



P0374

SeraQ Alinity V3



REF **P0374**



The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance



Table of contents

Intended Use.....	3
Key to Symbols Used.....	3
Principle of method.....	3
Traceability of antigen and antibody concentrations.....	4
Materials Provided.....	4
Materials not provided.....	4
Storage Instructions.....	5
Reagent preparation.....	5
Analytical Performance Characteristics.....	6
Expected assay response values on run control.....	8
Interpretation of Results.....	8
Limitations.....	13
References.....	14














Intended Use

P0374 SeraQ Alinity V3 is intended to be used on the Abbott Alinity s[®] platform in diagnostic and blood screening laboratories as an external run control in combination with the assays for the detection of hepatitis B surface antigen (HBsAg), antibodies to hepatitis C virus (anti-HCV) and antibodies to human immunodeficiency virus types 1 and 2 (anti-HIV-1/2). (see Table 1). P0374 SeraQ Alinity V3 is a multi-marker mixture of inactivated HBsAg, anti-HCV and anti-HIV-1 standards in defibrinated plasma giving a low reactive result in the Abbott Alinity s[®] Assays. The run control is intended for repeated testing in consecutive runs of the immunoassays over time by trained laboratory workers. By comparison of the sample to cut off (S/CO) values for the three markers found on P0374 SeraQ Alinity V3 one can monitor whether the analytical sensitivity of test runs is consistent. The run control should not be used to replace internal controls or calibrators in the test kits. The test result on the run control should not be used to reject the run or delay the release of test results on donor or patient samples.

Table 1 Test kits covered by this run control

Equipment	Agent	Assays
Abbott Alinity s [®]	Hepatitis B surface antigen (HBsAg) Anti-hepatitis C virus (anti-HCV) Anti-human immunodeficiency virus type 1 (anti-HIV-1)	Alinity s HBsAg Alinity s Anti-HCVII Alinity s HIV Ag/Ab Combo

Key to Symbols Used

						
Manufacturer	Lot number	Catalogue number	In vitro diagnostic medical device	Country of origin	Contains human blood derivatives	Store below -20°C
						
Expiry date	Number of controls	Caution	For IVD performance evaluation only	Unique device identification	Read instructions for use	

Principle of method

A series of SeraQ multi-marker run controls have been designed for monitoring HBsAg, anti-HCV and anti-HIV-1 test performance. The run control tubes are barcoded and can be placed at random positions in sample racks of the blood screening device. The tubes are comparable in size to donor blood collection tubes. The run controls are designed to mimic naturally occurring serum specimens with low reactivity for HBsAg, anti-HCV and anti-HIV-1. The analytical sensitivity of test kits from different manufacturers varies and therefore for each combination of test kits a separate multi-marker run control has been designed. This SeraQ run control series includes the product P0374 SeraQ Alinity V3 for which the composition is optimised for use with the Abbott Alinity s[®] test system. The P0374 SeraQ Alinity V3 run control is designed to generate assay response values (i.e. S/CO ratios) positioned in the low positive range of the assays. Routine use of external run controls enables laboratories to monitor day-to-day test performance and *in-vitro* medical

diagnostic device (IVD) reagent lot variation. After approval by the Notified Body a summary of the safety and performance of the P0374 SeraQ Alinity V4 run control will be published at the EUDAMED website of the European Union¹.

Traceability of antigen and antibody concentrations

For each HBsAg, anti-HCV and anti-HIV-1 an internal serum standard has been established² from which reference panels and run controls are prepared by gravimetrically recorded dilution steps. The undiluted S0001 standard for HBsAg is derived from the same purified heat-inactivated source material as is used for preparation of the 2nd WHO HBsAg adw2 (00/588) International Standard (IS)^{3,4}. Studies with the later established WHO international hepatitis B virus genotype reference panel showed that the heat-inactivation of HBsAg in the International Standard had little impact on the detectability in immunoassays⁵. The HBsAg concentration in the run control has been set at 0.088 IU/mL based on the dilution factor of the HBsAg standard^{2,3}. During manufacturing of SeraQ run controls the measurable HBsAg concentration reduces to a certain extent depending on the test method. One IU of heat inactivated HBsAg was found to be equivalent to 0.67 nanogram (ng) of HBsAg when historically calibrated against the first HBsAg standard established by the Paul Ehrlich Institute (1st PEI HBsAg standard), comparable to conversion factors of 0.58 and 0.71 reported in WHO collaborative studies^{3,4,6}. The S0001 HBsAg standard used for preparation of the SeraQ run controls has been instrumental in studies to establish the length of the pre-HBsAg infectious window period and the infectivity of HBsAg positive blood without detectable hepatitis B virus (HBV)-DNA^{7,8}. No unitage could be assigned to the internal standards for anti-HCV and anti-HIV-1 since international reference preparations are not available. The consistent concentration of the analytes in consecutive SeraQ run control batches is guaranteed by release testing against a reference batch of the run control kept frozen at -30°C. These reference batches are derived from the same undiluted internal standards that are used for manufacturing of the SeraQ run controls.

Materials Provided

The run control contains human serum and 0.01% (w/v) Thimerosal as preservative and is provided in two formats as detailed in Table 2.

Table 2. Description of P0374 SeraQ Alinity V3 kit formats and contents

Cat. Code	GTIN/UDI-DI code [^]	Quantity run control	Tube size	Claimed sample volume	Secondary packaging
P0374/01	8718719830191	60 x 2.3 mL	10 mL	2.2 mL (+overflow)	60 tube rack in box
P0374/02	8718719830192	10 x 2.3 mL	10 mL	2.2 mL (+overflow)	10 tubes in bag

[^] Global Trade Item Number = Unique Device Identification - Device Identifier (UDI-DI) code

The basic UDI code (or Global Model Number (GMN)) of the P0374 SeraQ Alinity V4 run control is 871871983P0374F7.

Materials not provided

Pipetting devices in IVD test systems, a vortex instrument for thorough mixing of samples prior to use and a water bath of 37°C for quickly thawing of run control are not provided.

Storage Instructions

Store unopened tubes at or below -20°C. For each Alinity instrument thaw one run control tube in a water bath of 37°C until ice clot has disappeared. After thawing, the run control tubes should be stored at 2°C to 8°C for no longer than one week.

Warning and precautions

P0374 SeraQ Alinity V3 run controls are prepared from serum standards, in which virus has been inactivated by validated methods applied in the plasma industry². Infectivity and inactivation data have been analysed to demonstrate absence of residual infectivity of HBV, HCV, and HIV-1 in the run controls². The serum matrix in the run controls has been tested for infectious disease markers by serologic and molecular screening methods. However, no screening strategy can offer complete assurance that products derived from human blood cannot transmit undetected infectious agents. The run control should only be used by trained laboratory workers who are aware of the potential risk of infectious agents in human serum samples and take the necessary precautions.

- SeraQ run controls should be handled with the normal preventive measures in a serology laboratory^{9,10}.
- This product contains human plasma and traces of biological source material of non-human origin (bovine thrombin).
- The use of the run control in other assay configurations should be avoided and is not supported by the manufacturer.
- Wear disposable gloves when handling samples.
- Do not eat drink, smoke or apply cosmetics in areas where specimens are handled.
- Do not pipette by mouth.
- If skin or mucous membrane exposure occurs, immediately wash the area with copious amounts of water.
- Disinfect spills using a 0.5% hypochlorite solution (1:10 v/v household bleach) or equivalent disinfectant.
- Dispose unused or spilled materials according to the normal practices for biological waste disposal in your institution.
- If precipitates are visible, mix the run controls for 2 minutes thoroughly using a vortex instrument.
- Do not use run controls beyond one-week storage at 2-8°C.
- Store run controls in an upright position.
- Validation of the diagnostic test results must be based on the specifications set by the manufacturer of the test kit and not be influenced by the test result on the run control.

Reagent preparation

- For first use of the run control thaw the tube quickly in a water bath at 37°C.
- Mix gently during thawing until contents are just thawed.
- Immediately after ice clot has disappeared remove the run control tube from the water bath.
- Before testing allow the run control tube to adapt to room temperature.
- Mix the run control tube thoroughly prior to use with a vortex instrument.
- Place the run control tube at the specified positions in the sample racks of the Alinity system for regular donor or patient samples.
- Test on the Abbott Alinity platform with the assays mentioned in Table 1 according to the manufacturer's instructions.
- Store the opened tube immediately after use at 2-8 °C (see storage instructions).

Analytical Performance Characteristics

SeraQ run controls have been designed by examination of the response curves on dilutions of the internal standards and as such relate to the analytical sensitivity of immunoassays. In the following paragraphs the essential analytical performance characteristics of SeraQ run controls are presented.

Dose response and analytical sensitivity

By analysing standard dilution series, the relationship between S/CO values and concentration of the analyte can be established^{11,12}. Plotting Log transformed Alinity s S/CO values against Log concentration of analyte using linear regression analysis enables calculation of correlation coefficients. Figures 1a-c show linear dose response relations in the Abbott Alinity s HBsAg, anti-HCVII and HIV-Ag/Ab Combo assays obtained after Log transformation of dilution factor and S/CO values.

Figure 1a. Dose response in Abbott Alinity s HBsAg assay. Log HBsAg S/CO values are plotted against log dilution of HBsAg standard ($r^2=0.99$).




Figure 1b. Dose response in Abbott Alinity s anti-HCV II assay. Log anti-HCV S/CO values are plotted against log dilution of anti-HCV standard ($r^2=0.99$).





Figure 1c. Dose response in Abbott Alinity s HIV Ag/Ab Combo assay. Log anti-HIV-1 S/CO values are plotted against log dilution of anti-HIV-1 standard ($r^2=0.99$).



Expected assay response values on run control

The expected results for the P0386 Abbott Alinity V4 run control are as follows:

1. HBsAg	range S/CO ratio:	2.4 – 3.6
2. Anti-HCV	range S/CO ratio:	2.9 – 4.0
3. Anti-HIV-1	range S/CO ratio:	2.6 – 4.4

Each Alinity reagent lot appears to have its own dose response curve and distribution of S/CO values on SeraQ run controls. This depends on the analytical sensitivity of the Abbott Alinity s reagent lots that are in use. Thus, it cannot be guaranteed that the assay response values will always fall within these ranges. P0374 SeraQ Alinity V3 run control serves as an independent standard for monitoring consistent analytical sensitivity of Abbott Alinity s reagent lots over time.

Interpretation of Results

Calculations

Subsequent test runs can be analysed by appropriate statistical approaches on the S/CO ratios obtained on the external control samples. A software system (DataQ Analytics) is available via the website www.bioqcontrol.com for entering S/CO values and generating a statistical report with the following calculations for preparing a Levey-Jennings Chart:

Transforming assay response values

To obtain the test kit batch specific reference values for each marker, an initial collection of at least 30 consecutive test results is required. Upon collecting additional data, the chart characteristics may be updated.

- The S/CO values for HBsAg, anti-HCV and anti-HIV are 'log normally' distributed. For the Abbott Alinity assays one should use the logarithm of S/CO ratios for calculation of the geometric mean and confidence interval as follows:
 - Calculate from each measurement the log S/CO value.
 - Calculate average and standard deviation on this log transformed values; log (Average) and log (Standard Deviation).
 - Calculate the (geometric) mean in S/CO ratio by taking the anti-log value of the log (Average).
 - Calculate Student-t-values belonging to the 95% and 99% CI for different number of observations (n) (Table 3).
 - Calculate the Log (95% and 99% CI) as follows:
 - Log (99% Lower limit): $\text{Log (Average)} - (99\%) \text{ Student-t-Value} \times \text{Log (Standard Deviation)}$
 - Log (95% Lower limit): $\text{Log (Average)} - (95\%) \text{ Student-t-Value} \times \text{Log (Standard Deviation)}$
 - Log (95% Upper limit): $\text{Log (Average)} + (95\%) \text{ Student-t-Value} \times \text{Log (Standard Deviation)}$
 - Log (99% Upper limit): $\text{Log (Average)} + (99\%) \text{ Student-t-Value} \times \text{Log (Standard Deviation)}$
 - Take the anti-log values for calculating the confidence limits in S/CO ratio. To visualize the individual S/CO values make a Levey-Jennings control chart on a linear scale. S/CO ratios plotted on a linear scale depict the upper 95% and 99% confidence limits at greater distance from the geometric mean S/CO value than the lower confidence limits (see Figure 2).

Levey-Jennings Chart

Figure 2a-c shows examples of Levey-Jennings charts for different Alinity assays on the P0374 SeraQ Alinity V3 run control as can be obtained from the statistical reports by the DataQ Analytics software system. The Levey-Jennings chart is a graph in which quality control results are plotted over subsequent test runs in time to give a visual indication when a laboratory test is (not) working well. The data points for each test run in the scatter plots in Figure 2 show the distance from the geometric mean S/CO ratio (green line in

graph) which is the expected response level for the run control. The orange and red lines represent the 95% and 99% CI respectively. The data represents individual measurements of different laboratories and instruments.

Table 3. Relation of Student t value and numbers of runs (n) to calculate confidence intervals.

Runs (n)	t-value at 95% C.I.	t-value at 99% C.I.
10	2.306	3.355
20	2.101	2.878
30	2.048	2.763
Infinite	1.960	2.576

Infinite equals the normal distribution

Figure 2. Levey-Jennings charts of P0374 SeraQ Alinity V3 run control results in Abbott Alinity s assays from different laboratories represented by the orange dots and blue dots for one laboratory and its peer group respectively. The average (green line) and 95% and 99% CI (orange and red lines) are log transformed as explained in the text.

Figure 2a. Abbott Alinity s HBsAg assay.




Figure 2b. Abbott Alinity s anti-HCVII assay.





Figure 2c. Abbott Alinity s HIV-Ag/Ab Combo assay



Interpretation

Knowing the 95% and 99% CI for generating a Levey-Jennings chart one can use Nelson rules¹³ to interpret values outside the predictive limits and for identifying trends and aberrant results. The statistical report generated by the DataQ Analytics system (on the website www.bioqcontrol.com) identifies these trends and outliers for the laboratory requesting the report.

- Negative or positive trends resulting from gradual changes in test performance and not reported by the internal kit controls and/or alert systems in the test robot, are indicative for a lack of maintenance, the need for recalibration of equipment, or degradation of reagents. These are systematic errors. In case a trend is recognised, the laboratory is encouraged to identify the root cause of the deviation.
- Aberrant results like a negative response on the run control or a result outside the 99% CI are indicative for incidental errors that need further investigation to identify the root cause. The identification of the root cause of aberrant results is beyond the scope of the intended use of the run controls.
- Differences between S/CO values of laboratories could be attributed to different reagent lots or run control batches that are in use. The statistical report that can be obtained from the DataQ Analytics system (available on www.bioqcontrol.com) compares the assay response values on different lab instruments, test reagent lots and run control batches.

Abbott Alinity Assay response values on P0374 SeraQ Alinity V3 run control

Table 4 gives an example of the test results reported by different laboratories that tested the P0374 SeraQ Alinity V3 run control in multiple Alinity s reagent lots and instruments.

Table 4. Abbott Alinity Assay s response values on P0374 SeraQ Alinity V3 run control reported by a few laboratories over a period of two years.

Alinity s Assay	n	geomean S/CO	95% CI S/CO	99% CI S/CO
HBsAg	4014	2.96	2.59 – 3.38	2.49 - 3.53
Anti-HCV II	4103	3.44	3.13 – 3.78	3.03 - 3.89
HIV Ab/Ag	4097	3.38	2.78 – 4.11	2.61 – 4.37

Variation in immunoassay reagent lots and run control batches

Variation in S/CO ratio on run controls reflects the difference in analytical sensitivity of assay runs and reagent lots. Different batches of SeraQ run controls are prepared from the same standards. Therefore, the composition of the multi-marker run controls is consistent from batch-to-batch. Multi-variance analysis shows that test reagent lots are a larger source of variation in S/CO values than run control batches. Table 5 shows an example of such a comparison of the Alinity s HIV-Ag/Ab assay S/CO response values obtained with different reagent lots on three P0374 SeraQ Alinity V3 run control batches tested by a few laboratories from January 2022 to December 2023.

Table 5. Geomean Alinity s HIV-Ag/Ab S/CO ratios (and 95% CI) found with different reagent lots on three batches of P0374 SeraQ Alinity V3 run control by a few laboratories over a period of two years.

Alinity s HIV-Ag/Ab reagent lots	P0386 SeraQ run control batches					
	B4350-003		B4350-004		B4350-005	
	n	Geomean S/CO (95% CI)	n	Geomean S/CO (95% CI)	n	Geomean S/CO (95% CI)
31187BE00	31	2.87 (2.37-3.47)				
34351BE00	172	2.86 (2.51-3.26)				
35406BE00	105	3.52 (3.15-3.94)	223	3.68 (3.34-4.07)		
37452BE00	150	3.52 (3.17-3.91)	195	3.73 (3.39-4.12)		
38494BE00	168	2.93 (2.72-3.16)	271	3.09 (2.64-3.62)		
41086BE00					89	3.47 (3.14-3.83)
42225BE00	256	3.36 (3.08-3.67)	785	3.64 (3.13-4.23)	46	3.29 (3.03-3.58)
44033BE00					83	3.46 (3.13-3.82)
46270BE00					120	3.48 (3.09-3.91)
47180BE00			42	3.75 (3.36-4.19)	83	3.67 (3.41-3.94)
48035BE00			67	3.76 (3.36-4.22)		
48229BE00			14	3.64 (3.09-4.28)	111	3.62 (3.34-3.93)
51084BE00					195	2.99 (2.69-3.33)
51404BE00					667	3.34 (2.89-3.86)
51672BE00					61	2.95 (2.74-3.19)
52199BE00					159	3.00 (2.73-3.31)

Limitations

- SeraQ run controls were designed for monitoring the analytical performance of serologic test systems. They cannot be used to evaluate the diagnostic sensitivity of the assays.
- The run control must not be substituted for the mandatory controls or calibrators provided with IVD test kits for calculating the cut off and/or criteria for releasing test results.
- The response values on the run controls should not be used to release or reject the test run but can be used as an aid in the assessment of analytical performance.
- The expected S/CO values and 99% predictive intervals have been established with a limited number of Alinity reagent lots. It cannot be guaranteed that S/CO values obtained with new reagent lots will always fall within these limits.
- Although the batch-to batch composition of SeraQ run controls is consistent some variation in the measurable potency of the serum standards in the run control batches cannot be avoided due to matrix effects and other manufacturing variables.

References

1. Summary of safety and performance (SSP) of P0374 SeraQ Alinity V4 run control. European Commission. To be published in EUDAMED – European Database on Medical devices.
2. Lelie PN, Van Drimmelen A.A.J. Preparation of inactivated viral standards: Safety assessment of quality control samples for viral seroogy and NAT assays in blood screening laboratories. BioQControl document number CE4006. www.bioqcontol.com
3. Schüttler GG, Wend UC, Faupel FM, Lelie PN, Gerlich HW. J Antigenic and physiochemical characterization of the 2nd International Standard for hepatitis B virus surface antigen (HBsAg). *J Clin Virol* 2010;47:238-42
4. Ferguson M, Heath A, Lelie N, Nübling M, Nick S, Gerlich W, et al. WHO Working Group on Hepatitis and HIV Diagnostic Kits. Report of a collaborative study to (1) assess the suitability of a candidate replacement International Standard for HBsAg and a reference panel for HBsAg and (2) to calibrate the candidate standard in IU. 2003. <http://www.who.int/bloodproducts/cs/en/031987.pdf>.
5. Chudy M, Scheiblaue H, Hanschmann H-M, Kress J, Nick S, Wend U, Schüttler C, Nübling CM, Gerlich WH. Performance of hepatitis B surface antigen tests with the first WHO international hepatitis B virus genotype reference panel. *J Clin Virol*. 2013;58:47-53
6. Gerlich W. H., Thomssen R. (1975) Standardized detection of hepatitis B surface antigen: determination of its serum concentration in weight units per volume. *Dev. Biol Stand* 1975;30:78-87
7. Van Drimmelen H, Lelie PN, Early dynamics of hepatitis B virus (HBV-DNA) and surface antigen (HBsAg) in ramp-up phase of viremia: Implications for performance evaluation of blood screening assays. *Viruses* 2022, 14, 1942 <https://doi.org/10.3390/v14091942>
8. Ekiaby ME, Tanaka J, Van Drimmelen H, Allain J-P, Lelie N. Infectivity of hepatitis B virus (HBV) surface antigen (HBsAg) positive plasma with undetectable HBV-DNA: Can HBsAg screening be discontinued in Egyptian blood donors? *J Viral Hepat*. 2022;29:330-339. doi:10.1111/jvh.13666.
9. Centers for Disease Control (CDC). Update: Universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. *MMWR* 1988; 37:377-388.
10. Centers for Disease Control (CDC). Guidelines for prevention of transmission of human immunodeficiency virus and hepatitis B virus to health-care and public-safety workers. *MMWR* 1989; 38(S-6): 1-36.
11. Plikaytis BD, Turner SH, Gheesling LL, Carlone GM. Comparisons of standard curve-fitting methods to quantitate *Neisseria meningitidis* group A polysaccharide antibody levels by enzyme-linked immunosorbent assay. *J Clin Microbiol*. 1991;29(7):1439-46
12. Bank HL. A quantitative enzyme-linked immunosorbent assay for rat insulin J Immunoassay. 1988; 9(2):135-58.
13. Nelson LS, "The Shewhart Control Chart—Tests for Special Causes". *Journal of Quality Technology* 1984;16, no. 4: 238-239



BioQControl B.V.
Droogmakerij 31h
1851 LX Heiloo
The Netherlands

Tel: +31 (0)72 2020 730
Fax: +31 (0)72 2020 731
Internet: www.BioQControl.com

KI4280 V6.0
January 2024